dc.contributor.author | Dønnem, Tom | |
dc.contributor.author | Lønvik, Kenneth | |
dc.contributor.author | Eklo, Katrine | |
dc.contributor.author | Berg, Thomas | |
dc.contributor.author | Sørbye, Sveinung Wergeland | |
dc.contributor.author | Al-Shibli, Khalid Ibrahim | |
dc.contributor.author | Al-Saad, Samer | |
dc.contributor.author | Andersen, Sigve | |
dc.contributor.author | Stenvold, Helge | |
dc.contributor.author | Bremnes, Roy M. | |
dc.contributor.author | Busund, Lill-Tove | |
dc.date.accessioned | 2012-03-27T08:12:04Z | |
dc.date.available | 2012-03-27T08:12:04Z | |
dc.date.issued | 2011 | |
dc.description.abstract | Angiogenesis is pivotal in tumor development. Vascular endothelial growth factor-A (VEGF-A) is considered one of the most important angiogenic factors, but lately several microRNAs (miRs) have been associated with vascular development. miR-126 has been related to tumor angiogenesis and in the regulation of VEGF-A. The authors aimed to investigate the prognostic impact of miR-126 and its co-expression with VEGF-A in nonsmall cell lung cancer (NSCLC) patients. Tumor tissue samples from 335 resected stage I to IIIA NSCLC patients were obtained and tissue microarrays (TMAs) were constructed with 4 cores from each tumor specimen. VEGF-A expression was evaluated by immunohistochemistry, and in situ hybridization was used to evaluate the expression of miR-126. In the total material, miR-126 was a significant negative prognostic factor in both univariate (P = .005) and multivariate analyses (hazard ratio [HR] 1.8, 95% confidence interval [CI] 1.2-2.8, P = .01). Stratified by histology, miR-126 was only significant in squamous cell carcinomas (univariate: P < .001; multivariate: HR 3.1, CI 95% 1.7-5.6, P<.001). Stratified by lymph node status, miR-126 was significant only in the lymph node-positive subgroup (univariate: P<.001; multivariate: HR 4.1, CI 95% 2.0-8.4, P < .001). High miR-126 expression correlated significantly with high VEGF-A expression (P = .037). The co-expression of miR-126 and VEGF-A had a significant prognostic impact (P = .002), with 5-year survival rates of 68%, 51%, and 42% for low/low (n = 150), mixed combinations (n = 129), and high/high (n = 35) expression, respectively. miR-126 is a strong and independent negative prognostic factor in NSCLC, and its prognostic impact appears related primarily to histology and nodal status. Cancer 2011. © 2011 American Cancer Society. | en |
dc.identifier.citation | Cancer 117(2011) nr. 14 s. 3193-3200 | en |
dc.identifier.cristinID | FRIDAID 836229 | |
dc.identifier.doi | doi: 10.1002/cncr.25907 | |
dc.identifier.issn | 0008-543X | |
dc.identifier.uri | https://hdl.handle.net/10037/4072 | |
dc.identifier.urn | URN:NBN:no-uit_munin_3792 | |
dc.language.iso | eng | en |
dc.publisher | John Wiley & Sons, Ltd. | en |
dc.rights.accessRights | openAccess | |
dc.subject | VDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::General pathology, anatomical pathology: 719 | en |
dc.subject | VDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Generell patologi, patologisk anatomi: 719 | en |
dc.subject | VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762 | en |
dc.subject | VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 | en |
dc.title | Independent and Tissue-Specific Prognostic Impact of miR-126 in Nonsmall Cell Lung Cancer | en |
dc.type | Journal article | en |
dc.type | Tidsskriftartikkel | en |
dc.type | Peer reviewed | en |